		Initial ser	ies cohort		Third dose cohort				
Threshold for defining undiagnosed infection by an increase in titer	100 BAU/mL		200 BA	AU/mL	100 BAU/mL		200 BAU/mL		
	n (%)	% of infections	n (%)	% of infections	n (%)	% of infections	n (%)	% of infections	
Diagnosed SARS-CoV-2 infection	371 (14%)	76%	379 (14%)	82%	155 (9%)	80%	155 (9%)	87%	
Undiagnosed SARS-CoV-2 infection	115 (4%)	24%	85 (3%)	18%	39 (2%)	20%	23 (1%)	13%	
No SARS-CoV-2 infection	2174 (82%)		2196 (83%)		1523 (89%)		1539 (90%)		
Total	2660		2660		1717		1717		

**Supplemental Table 1**. Identification of undiagnosed SARS-CoV-2 infections by increase in anti-spike IgG titer. An increase of 100 BAU/mL in the 3-month rolling average titer was used as the primary analysis, and an increase of 200 BAU/mL was used in a sensitivity analysis.

No prior COVID-19						Prior COVID-19					
		Initial series						Initial series			
		J	MM	PP	Total			J	MM	PP	Total
Third dose	J	18	0	1	19	Third dose	J	5	0	0	5
	М	25	640	91	756		М	1	124	15	140
	M/2	49	111	6	166		M/2	6	11	0	17
	Р	24	230	522	776		Р	6	29	91	126
	Total	116	981	620	1717		Total	18	164	106	288

**Supplemental Table 2**. Among those who received a third (additional) vaccine dose, the breakdown of vaccine type received, by initial vaccine series and by third dose. Here, each capital letter (J, M, or P) represents a single dose of Janssen, Moderna, or Pfizer vaccine, respectively. M/2 represents half-dose Moderna.